Utilising Health Technology Assessment to Develop Managed Access Protocols to Facilitate Drug Reimbursement in Ireland.
利用健康技術評估制定管理訪問協議以促進愛爾蘭的藥物報銷。
Appl Health Econ Health Policy 2024-08-12
Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care.
肥胖症的治療進展:現實世界證據如何影響超越標準護理的可負擔性。
Pragmat Obs Res 2024-08-12
Changes in glomerular filtration rate in patients with body mass index ≥35 kg/m<sup>2</sup> treated with metabolic and bariatric surgery versus GLP-1 agonist at 1-year follow-up.
體重指數 ≥35 kg/m<sup>2</sup> 患者在接受代謝及減重手術與 GLP-1 激動劑治療後 1 年隨訪的腎小球過濾率變化。
Obes Sci Pract 2024-08-12
Potassium voltage-gated channel subfamily H member 2 (KCNH2) is a promising target for incretin secretagogue therapies.
鉀電壓閘道通道亞家族 H 成員 2 (KCNH2) 是一個有前景的促胰島素分泌療法的靶點。
Signal Transduct Target Ther 2024-08-11
AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys.
AT-7687,一種新型 GIPR 肽拮抗劑,與 GLP-1 激動劑聯合使用,可促進猕猴的體重減輕和代謝改善。
Mol Metab 2024-08-11
Glucagon-like peptide-1 receptor agonists and risk of sight-threatening retinopathy in Taiwanese population: A propensity based cohort study.
台灣人口中胰高血糖素樣肽-1受體激動劑與視力威脅性視網膜病變風險:一項基於傾向得分的隊列研究。
Diabetes Metab Syndr 2024-08-11
Cardioprotective benefits of metabolic surgery and GLP-1 receptor agonist-based therapies.
代謝手術和GLP-1受體激動劑療法的心臟保護益處。
Trends Endocrinol Metab 2024-08-10